These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 21152861)

  • 1. Isolation and characterization of gemcitabine-resistant human non-small cell lung cancer A549 cells.
    Ikeda R; Vermeulen LC; Lau E; Jiang Z; Sachidanandam K; Yamada K; Kolesar JM
    Int J Oncol; 2011 Feb; 38(2):513-9. PubMed ID: 21152861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Mechanisms of the drug resistance of a 2', 2-difluorodeoxycytide (gemcitabine)-resistant variant of the human lung adenocarcinoma cell line].
    Dong M; Feng FY; Lin C; Zhang XY; Fu M; Liang X; Zha YY; Lu HY; Wu M
    Zhonghua Yi Xue Za Zhi; 2004 Feb; 84(4):323-8. PubMed ID: 15059518
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Array analysis for potential biomarker of gemcitabine identification in non-small cell lung cancer cell lines.
    Zhang HH; Zhang ZY; Che CL; Mei YF; Shi YZ
    Int J Clin Exp Pathol; 2013; 6(9):1734-46. PubMed ID: 24040438
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines].
    Liu XQ; Wang WX; Lin L; Song ST
    Zhonghua Zhong Liu Za Zhi; 2010 Jan; 32(1):17-21. PubMed ID: 20211060
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Determinants of sensitivity and resistance to gemcitabine: the roles of human equilibrative nucleoside transporter 1 and deoxycytidine kinase in non-small cell lung cancer.
    Achiwa H; Oguri T; Sato S; Maeda H; Niimi T; Ueda R
    Cancer Sci; 2004 Sep; 95(9):753-7. PubMed ID: 15471562
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The role of thymidylate synthase and dihydropyrimidine dehydrogenase in resistance to 5-fluorouracil in human lung cancer cells.
    Oguri T; Achiwa H; Bessho Y; Muramatsu H; Maeda H; Niimi T; Sato S; Ueda R
    Lung Cancer; 2005 Sep; 49(3):345-51. PubMed ID: 15993511
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.
    Denlinger CE; Rundall BK; Keller MD; Jones DR
    Ann Thorac Surg; 2004 Oct; 78(4):1207-14; discussion 1207-14. PubMed ID: 15464472
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy resistance and oncogene expression in non-small cell lung cancer.
    d'Amato TA; Landreneau RJ; Ricketts W; Huang W; Parker R; Mechetner E; Yu IR; Luketich JD
    J Thorac Cardiovasc Surg; 2007 Feb; 133(2):352-63. PubMed ID: 17258563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The determinants of sensitivity and acquired resistance to gemcitabine differ in non-small cell lung cancer: a role of ABCC5 in gemcitabine sensitivity.
    Oguri T; Achiwa H; Sato S; Bessho Y; Takano Y; Miyazaki M; Muramatsu H; Maeda H; Niimi T; Ueda R
    Mol Cancer Ther; 2006 Jul; 5(7):1800-6. PubMed ID: 16891466
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Development and characterization of a gemcitabine-resistant variant of human lung adenocarcinoma cell line A549].
    Dong M; Lin C; Feng FY; Zhang XY; Fu M; Liang X; Lu HY; Zha YY; Wu M
    Ai Zheng; 2004 Jun; 23(6):667-71. PubMed ID: 15191667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction between gemcitabine and topotecan in human non-small-cell lung cancer cells: effects on cell survival, cell cycle and pharmacogenetic profile.
    Giovannetti E; Mey V; Danesi R; Basolo F; Barachini S; Deri M; Del Tacca M
    Br J Cancer; 2005 Feb; 92(4):681-9. PubMed ID: 15700043
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Suberoylanilide hydroxamic acid combined with gemcitabine enhances apoptosis in non-small cell lung cancer.
    Rundall BK; Denlinger CE; Jones DR
    Surgery; 2005 Aug; 138(2):360-7. PubMed ID: 16153448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.
    Davidson JD; Ma L; Flagella M; Geeganage S; Gelbert LM; Slapak CA
    Cancer Res; 2004 Jun; 64(11):3761-6. PubMed ID: 15172981
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNNC1 Reduced Gemcitabine Sensitivity of Nonsmall-Cell Lung Cancer by Increasing Autophagy.
    Ye X; Xie G; Liu Z; Tang J; Cui M; Wang C; Guo C; Tang J
    Med Sci Monit; 2020 Sep; 26():e922703. PubMed ID: 32946432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. siRNA silencing EZH2 reverses cisplatin-resistance of human non-small cell lung and gastric cancer cells.
    Zhou W; Wang J; Man WY; Zhang QW; Xu WG
    Asian Pac J Cancer Prev; 2015; 16(6):2425-30. PubMed ID: 25824776
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relationship between miR-17-5p, miR-92a, and let-7b expression with non-small cell lung cancer targeted drug resistance.
    Gong J; He L; Ma J; Zhang J; Wang L; Wang J
    J BUON; 2017; 22(2):454-461. PubMed ID: 28534369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine inhibits the micrometastasis of non-small cell lung cancer by targeting the EpCAM-positive circulating tumor cells via the HGF/cMET pathway.
    Liao ZJ; Guo YH; Zhao Z; Yao JT; Xu R; Nan KJ
    Int J Oncol; 2014 Aug; 45(2):651-8. PubMed ID: 24867356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. UbcH10 expression provides a useful tool for the prognosis and treatment of non-small cell lung cancer.
    Zhao L; Jiang L; Wang L; He J; Yu H; Sun G; Chen J; Xiu Q; Li B
    J Cancer Res Clin Oncol; 2012 Nov; 138(11):1951-61. PubMed ID: 22760214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduced miR-363-3p expression in non-small cell lung cancer is associated with gemcitabine resistance via targeting of CUL4A.
    Bian WG; Zhou XN; Song S; Chen HT; Shen Y; Chen P
    Eur Rev Med Pharmacol Sci; 2019 Jan; 23(2):649-659. PubMed ID: 30720173
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The absence of human equilibrative nucleoside transporter 1 expression predicts nonresponse to gemcitabine-containing chemotherapy in non-small cell lung cancer.
    Oguri T; Achiwa H; Muramatsu H; Ozasa H; Sato S; Shimizu S; Yamazaki H; Eimoto T; Ueda R
    Cancer Lett; 2007 Oct; 256(1):112-9. PubMed ID: 17658213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.